Zevra Therapeutics Inc (ZVRA) posted $37.8 million in Q3 2026 revenue, swung to $19.2 million net income, and outlined plans for an infant label expansion and a Q4 European decision on arimoclomol.
$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA 45% increase in total net revenue over Q3 2025 Operational execution fueled strong cash position of $270.9 million Company to host conference call and webcast TODAY, November 3, 2026, at 4:30 p.m. ET BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with
Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. Learn more about ZVRA stock here.
Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations
This is the newest page. Registered accounts read further back.